Transitional cell carcinoma (TCC) is one of the most common cancers of the canine urinary tract. Existing treatment options for this disease have resulted in only modest benefit. Studies in both humans and dogs suggest tyrosine kinase inhibitors can provide a benefit in controlling disease progression for various solid tumors. Toceranib phosphate (Palladia®, Pfizer) is a FDA approved multi-targeted tyrosine kinase inhibitor for dogs with mast cell tumor. The purpose of this study is to evaluate the safety and potential efficacy (tumor response) of toceranib phosphate in management of canine transitional cell carcinoma.
Dogs with TCC who have had tumor progression while receiving non-steroidal anti-inflammatory drugs (NSAID). Dogs must have a measurable tumor on abdominal ultrasounds.
Dogs with other significant medical conditions, kidney problems or GI ulcers that may limit the use of NSAIDs are ineligible from participating in this study.
The owner is financially responsible for all tests that determine if the patient qualifies for the study. These tests may include abdominal ultrasounds, chest X-rays, blood and urine tests.
This study covers the cost of a limited number and portion of re-check examination fees, pre-treatmentCBC/platelet counts, abdominal ultrasounds, and chemistry profiles. Toceranib phosphate will be provided to the owner at no charge.
Kelly Reed, Oncology Liaison